European Commission approves Takeda's recombinant ADAMTS13 therapy (ADZYNMA®) for cTTP, a rare disease.

European Commission approves ADZYNMA® (recombinant ADAMTS13) as the first recombinant ADAMTS13 replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP), offering a new treatment option for rare disease patients. Takeda's product, the only enzyme replacement therapy for cTTP in the EU, received approval after demonstrating favorable safety and efficacy results in a Phase 3 trial.

August 07, 2024
3 Articles